Cell Lysis News and Research

RSS

Themis, Max-Planck-Innovation sign license agreement to develop and commercialize oncolytic virotherapies

Themis announced today that it has entered into a license agreement with Max-Planck-Innovation GmbH, the technology transfer agency of the Max Planck Society in Germany, granting it exclusive worldwide license to develop, manufacture and commercialize therapies based on an oncolytic measles virus platform that was jointly developed by the Eberhard-Karls-University Tübingen and the Max Planck Institute for Biochemistry. Financial terms of the agreement were not disclosed.

11 Oct 2018

Researchers streamline design of lab-on-a-chip devices to observe their inner workings

Microfluidic devices can take standard medical lab procedures and condenses each down to a microchip that can balance on top of a water bottle lid.

6 Oct 2018

$Bacterial therapy shows early clinical efficacy in patients with treatment-refractory solid tumors$

Bacterial therapy shows early clinical efficacy in patients with treatment-refractory solid tumors

A phase I clinical trial investigating the use of bacterial Clostridium novyi-NT spores as an injectable monotherapy had manageable toxicities and showed early clinical efficacy in patients with treatment-refractory solid tumor malignancies, according to data presented at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, held Sept. 30-Oct. 3.

30 Sep 2018

Researchers synthesize new antibacterial polymers without hydrophobic alkyl chains

Artificial polymers, like antibiotic peptides, need both hydrophobic and hydrophilic domains in their molecular structure to exert antibacterial activity.

7 Sep 2018

Modifying Oncolytic Adenoviruses to Target Pancreatic Cancer

Pancreatic cancer is one of the less common but deadliest cancers. Modified oncolytic adenoviruses represent an alternative to chemotherapy and targeted therapies, which have a high mortality rate.

9 Mar 2018

New ChIPseq kit is optimized for fresh and frozen tissue samples

The new, high-performance Chromatrap ChIP-Seq kit (v.1.5) is optimized to work from fresh and frozen extracted tissue, as well as cell lines.

From Chromatrap® - Porvair Sciences Ltd 2 Feb 2018

CAR T cell therapy shows long-lasting remissions in non-Hodgkin's lymphoma patients

In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) patients.

11 Dec 2017

FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence

The U.S. Food and Drug Administration today approved Sutent (sunitinib malate) for the adjuvant treatment of adult patients who are at a high risk of kidney cancer (renal cell carcinoma) returning after a kidney has been removed (nephrectomy).

17 Nov 2017

American scientists develop bioorthogonal labeling test to assess sialylated glycans in tumor cells

Glycosylated proteins are often overexpressed in tumor cells and thus could serve as tumor markers, especially those with the interesting molecule sialic acid as their sugar moiety.

28 Jun 2017

Combining oral drug with personalized cell therapy can lead to complete remission in CLL patients

Combining the kinase inhibitor ibrutinib with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman School of Medicine at the University of Pennsylvania and Penn's Abramson Cancer Center

31 May 2017

Scientists develop easy-to-use diagnostic test that could rapidly detect flu

The threat of a major flu pandemic is a perennial concern. Now scientists have developed a fast and easy-to-use point-of-care diagnostic test that could one day help doctors and hospitals head off the rapid spread of the flu.

10 May 2017

New method for diagnosing flu virus from breath samples could provide faster results

A method for diagnosing flu virus from breath samples could soon replace invasive nasal swabs and deliver better results faster.

29 Mar 2017

Researchers develop new lab-on-a-chip platform that aims to improve pathogen detection

Nuclear amplification testing is commonly used for pathogen detection; however, the process is currently manually intensive and complex, and requires dedicated equipment. This prevents its use in some settings, and pathogen detection in individual samples.

24 Mar 2017

Decision-making process of tiniest viruses could lead to better treatments for diseases

Humans face hundreds of decisions every day. But we're not alone. Even the tiniest viruses also make decisions, and scientists are researching how they do so, to help lead to better treatments for some diseases.

7 Feb 2017

Valo Therapeutics develops novel oncolytic viral vaccines for treatment of multiple forms of cancer

A spin-out from the University of Helsinki, Valo Therapeutics is developing novel oncolytic viral vaccines for the treatment of multiple forms of cancer.

31 Jan 2017

Researchers provide insights into how phages exhibit high level of precision in cell destruction

Phage therapy, which exploits the ability of certain viruses to infect and replicate within bacteria, shows promise for treating antibiotic-resistant bacterial infections.

11 Jan 2017

Eppendorf Advantage supports smart, safe and stress-free environment for research labs

Eppendorf has announced the latest Advantage promotion period, until December 31st 2016, on a range of best-in-class solutions which drive productivity in the laboratory.

From Eppendorf 8 Sep 2016

Chromatrap describes methodologies to increase ChIP efficiency

Chromatrap, a business unit of Porvair Sciences, has published a new technical article that discusses and describes methodologies to increase Chromatin Immunoprecipitation efficiency by making sure chromatin in your samples is sheared to the correct size range.

From Chromatrap® - Porvair Sciences Ltd 19 Jul 2016

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year.

6 Jul 2016

Fecal transplants transfer bacterial viruses that appear to be harmless to humans

Communities of viruses can be transferred during fecal transplants, according to a study published this week in mBio, an online open-access journal of the American Society for Microbiology. Fortunately for patients who use this procedure, the viruses found to be transmitted in this study appear to be harmless to humans.

30 Mar 2016